Abstract
Current and former FDA officials and outside experts attended a wide-ranging forum in March to discuss regulatory obstacles and opportunities in bringing new cancer drugs to the market. During the two-day seminar, held at the Washington, D.C., headquarters of the American Enterprise Institute for
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
